ImmunityBio (NASDAQ:IBRX) Earns Buy Rating from D. Boral Capital

Key Points

• D. Boral Capital reiterated a "buy" on ImmunityBio with a $23 price target, implying roughly a 235% upside from the stock's recent level (around $6.86).
• The company faces significant regulatory risk after the FDA flagged potentially misleading efficacy claims for its lead asset Anktiva, which triggered a ~21% share plunge and multiple securities class-action filings, though ImmunityBio says it has submitted a comprehensive response and saw a modest ~3% intraday rebound.
• Analysts have a consensus of "Moderate Buy" with an average target of $14.40; insiders have sold ~501,967 shares (~$4.47M) in the past three months despite insiders owning ~69.5% of shares, and the stock trades with a market cap of about $7.05 billion.

ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $23.00 price objective on the stock. D. Boral Capital's target price would suggest a potential upside of 235.28% from the stock's current price.

Other research analysts also recently issued reports about the stock. Jefferies Financial Group increased their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, December 12th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of ImmunityBio in a research report on Monday, December 29th. HC Wainwright increased their target price on shares of ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, February 23rd. The Goldman Sachs Group reaffirmed a "buy" rating on shares of ImmunityBio in a research report on Monday, February 23rd. Finally, BTIG Research initiated coverage on shares of ImmunityBio in a research report on Thursday, March 12th. They issued a "buy" rating and a $13.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $14.40.

ImmunityBio Trading Down 3.1%

Shares of NASDAQ:IBRX opened at $6.86 on Wednesday. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $12.43. The company's 50 day moving average is $7.78 and its two-hundred day moving average is $4.46. The company has a market cap of $7.05 billion, a PE ratio of -18.05 and a beta of 0.13.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. As a group, equities research analysts expect that ImmunityBio will post -0.92 EPS for the current year.

Insider Buying and Selling at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 50,000 shares of the firm's stock in a transaction on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the firm's stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the transaction, the director directly owned 2,925,821 shares in the company, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 501,967 shares of company stock worth $4,466,412 over the last three months. 69.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of IBRX. Slow Capital Inc. purchased a new position in ImmunityBio during the 3rd quarter worth $25,000. Truist Financial Corp acquired a new stake in shares of ImmunityBio in the 3rd quarter worth $27,000. Swiss Life Asset Management Ltd acquired a new stake in shares of ImmunityBio in the 3rd quarter worth $27,000. WealthPlan Investment Management LLC acquired a new stake in shares of ImmunityBio in the 4th quarter worth $27,000. Finally, Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio in the 2nd quarter worth $27,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio says it submitted a comprehensive response to the FDA's OPDP concerns, confirmed the TV ad was never aired, addressed the podcast issues and pledged tighter advertising oversight — a compliance step that could limit further regulatory damage. ImmunityBio Addresses FDA Correspondence
• Positive Sentiment: Some market coverage noted an immediate, modest rebound after the company's compliance response (reports of a ~3% intraday uptick), suggesting short-term relief for investors who view the company’s corrective actions as credible. ImmunityBio Stock Gains 3%
• Positive Sentiment: At least one sell-side commentary (BTIG) remains constructive on IBRX despite the OPDP action, which may temper longer-term selling if commercial momentum and clinical data continue to support the story. ImmunityBio Faces FDA Warning, BTIG Stays Positive
• Neutral Sentiment: Coverage highlights the company’s stated compliance fixes alongside ongoing sales/expansion efforts; investors will watch whether operational performance offsets reputational/regulatory risk. IBRX Responds to FDA Warning
• Neutral Sentiment: Some analysts and outlets speculate shorter-term technical snapshots (e.g., whether the stock will "snap" a brief losing streak) and focus on upcoming data links for Anktiva; these are market-moving only if new data or guidance appears. IBRX Stock Set to Snap 2 Days of Losses?
• Negative Sentiment: Regulatory action sparked a major market reaction: headlines noted a sharp (~21%) prior share plunge after the FDA flagged potentially misleading efficacy claims for Anktiva — an event that materially increases reputational and litigation risk for the company. IBRX Shareholder Update - Hagens Berman
• Negative Sentiment: Multiple law firms have filed securities class actions or are soliciting lead-plaintiff applications alleging misleading statements about Anktiva; dozens of counsel notices cite a May 26, 2026 deadline to seek lead-plaintiff status — this concentrated litigation activity is a clear near-term negative for valuation and shareholder sentiment. ImmunityBio Securities Fraud Class Action - Kahn Swick

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.